Docoh
Loading...

ANAB AnaptysBio

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Company profile

Ticker
ANAB
Exchange
CEO
Hamza Suria
Employees
Incorporated
Location
Fiscal year end
Former names
ANAPTYS BIOSCIENCES INC, ANAPTYSBIO INC
SEC CIK

ANAB stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 May 21
17 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AnaptysBio earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 284.21M 284.21M 284.21M 284.21M 284.21M 284.21M
Cash burn (monthly) (positive/no burn) (positive/no burn) 6.12M 2.67M 7.73M 1.85M
Cash used (since last report) n/a n/a 9.59M 4.18M 12.13M 2.91M
Cash remaining n/a n/a 274.61M 280.03M 272.08M 281.3M
Runway (months of cash) n/a n/a 44.9 105.1 35.2 151.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 May 21 Suria Hamza Common Stock Option exercise Aquire M No No 1.12 10,000 11.2K 57,636
12 May 21 Suria Hamza Employee Stock Option Common Stock Option exercise Dispose M No No 1.12 10,000 11.2K 30,361
4 May 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 23.247 165,000 3.84M 7,520,424
3 May 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 23.3112 20,800 484.87K 7,355,424
30 Apr 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 23.1601 35,700 826.82K 7,334,624
27 Apr 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 23.8192 33,800 805.09K 7,298,924
26 Apr 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 23.8028 13,900 330.86K 7,265,124
23 Apr 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 23.537 99,600 2.34M 7,251,224
9 Mar 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 18.6976 531,000 9.93M 7,151,624
8 Mar 21 EcoR1 Capital Common Stock Buy Aquire P Yes No 18.9698 2,777,800 52.69M 6,620,624

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 136 131 +3.8%
Opened positions 24 21 +14.3%
Closed positions 19 13 +46.2%
Increased positions 36 31 +16.1%
Reduced positions 45 51 -11.8%
13F shares
Current Prev Q Change
Total value 729.48M 429.49M +69.8%
Total shares 31.49M 29.12M +8.1%
Total puts 64.2K 74.4K -13.7%
Total calls 182.1K 1.2K +15075.0%
Total put/call ratio 0.4 62.0 -99.4%
Largest owners
Shares Value Change
EcoR1 Capital 3.22M $69.3M 0.0%
Tang Capital Partners 2.63M $56.52M NEW
Tang Capital Management 2.63M $56.52M 0.0%
Vanguard 2.22M $47.74M +7.6%
BLK Blackrock 1.91M $41.02M -1.2%
FHI Federated Hermes 1.32M $28.37M -6.2%
Boxer Capital 1.3M $27.95M 0.0%
Aquilo Capital Management 1.22M $26.14M -17.7%
STT State Street 1.22M $26.14M +1.8%
Perceptive Advisors 1.2M $25.7M NEW
Largest transactions
Shares Bought/sold Change
Tang Capital Partners 2.63M +2.63M NEW
Frazier Management 899.7K -1.42M -61.2%
BVF 0 -1.23M EXIT
Perceptive Advisors 1.2M +1.2M NEW
Frazier Healthcare V 899.7K +899.7K NEW
Point72 Asset Management 760.3K +760.3K NEW
Sessa Capital IM 166.7K -360.7K -68.4%
TROW T. Rowe Price 332.9K +332.9K NEW
Burrage Capital Management 0 -330.55K EXIT
Aquilo Capital Management 1.22M -261.69K -17.7%

Financial report summary

?
Competition
PfizerAMGENXOMAIncyteAstrazenecaRocheNovartisSanofiLyra TherapeuticsAbbvie
Risks
  • Risks Related to Discovery and Development of Our Product Candidates
  • Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. Results from our initial clinical trials may not be representative of the results we will experience in later clinical trials. If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.
  • We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates.
  • We may not be successful in our efforts to use our technology platform to expand our pipeline of product candidates and develop marketable products.
  • We have recently commenced clinical development of imsidolimab, ANB030 and ANB032 and have a limited history of conducting clinical trials and no history of commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability.
  • We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
  • Our product candidates may not achieve adequate market acceptance among physicians, patients, health care payors and others in the medical community necessary for commercial success.
  • If companion diagnostics for our product candidates, for which such diagnostics are required, are not successfully, and in a timely manner, validated, developed or approved, we may not achieve marketing approval or realize the full commercial potential of our product candidates.
  • The manufacture of biologics is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.
  • Risks Related to Our Financial Position and Capital Needs
  • We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from sales of our product candidates.
  • We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.
  • Risks Related to Managing Growth, Operations and Macroeconomic Conditions
  • We must attract and retain highly skilled employees in order to succeed.
  • We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • We may be vulnerable to disruption, damage and financial obligation as a result of system failures.
  • Our operations, or the third parties upon whom we depend, are vulnerable to interruption by fire, earthquake, power loss, telecommunications failure, terrorist activity, health epidemics or pandemics and other events beyond our control, which could harm our business.
  • Risks Related to Our Dependence on Third Parties
  • Our existing collaborations, including those with GSK and BMS, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.
  • We may not succeed in establishing and maintaining additional development and commercialization collaborations, which could adversely affect our ability to develop and commercialize product candidates.
  • If third parties on which we depend to conduct our planned preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects on our business, financial condition, results of operations and prospects.
  • We rely completely on third parties to manufacture our nonclinical, clinical and future commercial drug supplies of any approved products.
  • We depend on a small number of suppliers for the raw materials necessary to produce our product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.
  • Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
  • Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements.
  • Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.
  • Any drugs we develop may become subject to unfavorable third-party reimbursement practices and pricing regulations.
  • Healthcare legislative reform measures may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • Our business entails a significant risk of product liability, and our ability to obtain sufficient insurance coverage could have an adverse effect on our business, financial condition, results of operations or prospects.
  • Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other health care laws and regulations, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.
  • Risks Related to Intellectual Property
  • If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business.
  • If we breach the license agreements related to our product candidates, we could lose the ability to continue the development and commercialization of our product candidates.
  • Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights, or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.
  • We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.
  • Our inability to protect our confidential information and trade secrets would harm our business and competitive position.
  • If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be harmed.
  • Risks Related to Ownership of Our Common Stock
  • The market price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.
  • We have broad discretion in the use of the net proceeds from our public offerings and may not use them effectively.
  • We may be subject to securities litigation, which is expensive and could divert management attention.
  • The requirements of being a public company may strain our resources, divert management’s attention, and affect our ability to attract and retain additional executive management and qualified board members.
  • Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
  • We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.
  • Provisions in our restated certificate of incorporation and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • We plan to use potential future operating losses and our federal and state net operating loss (“NOL”) carryforwards to offset taxable income from revenue generated from operations or corporate collaborations. However, our ability to use NOL carryforwards could be limited as a result of additional issuances of equity securities.
Management Discussion
  • Collaboration revenue was $75.0 million compared to $8.0 million for the years ended December 31, 2020 and 2019, respectively. A comparison of collaboration revenue is as follows:
  • Collaboration revenue during the year ended December 31, 2020 increased $67.0 million compared to the year ended December 31, 2019 primarily due to payment received related to an amendment to the GSK Agreement during 2020 and the timing of milestones achieved.
  • We expect that any collaboration revenue we generate will continue to fluctuate from period to period as a result of the timing and amount of milestones from our existing collaborations.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Accutane, acid, acne, ACORN, adapalene, aimed, alopecia, Amnesteem, API, apportioned, areata, arm, Avage, Avita, BBA, Benzaclin, Benzamycin, Biden, billing, Brexit, buy, calcineurin, carcinoma, cervical, Classification, clindamycin, codified, contact, CPRA, CTN, delete, deliverable, detailed, dibutyl, Differin, dinitrochlorobenzene, diphencyprone, dismissed, draft, Duac, epidemiology, erythromycin, ester, evolving, expression, fifty, flexibility, group, harder, HARP, healthcare, hereinafter, HHS, imaging, implanted, infiltration, inhaled, INSPIRE, instilled, instructed, intent, inversa, IQVIA, isotretinoin, issuer, iv, ix, JEMPERLI, journey, knowledge, lag, Lanham, licensure, lowest, LSMD, Merck, modification, nationwide, neutrophil, nondeductible, nonexclusive, Northern, Notification, numerically, opt, outpatient, oversee, Pacific, painful, Pandion, parent, pattern, PdMMRT, pharmacokinetic, platinum, possession, poverty, PPPASI, PPPIGA, predominant, prejudice, procurement, progressed, progression, proscribed, proxy, rebate, recognition, rectal, regimen, relaxing, Revision, rixolitinib, sarcoma, sarecycline, scarring, secondary, seventy, Seysara, squaric, stricter, sublease, suppurativa, surgery, tazarotene, Tazorac, temporary, tie, titled, tofacitinib, tretinoin, Trex, trillion, tumor, UK, unclear, unconstitutional, unfair, upregulated, urged, vi, vii, viii, vitiligo, voluntarily, women
Removed: actively, acute, aforementioned, AFS, aged, alpha, AMG, Amgen, amortized, anrukinzumab, asthma, AstraZeneca, ASU, benralizumab, bind, Bio, book, borrow, calculating, capacity, categorized, China, CHIP, Cinqair, close, computation, Connecticut, content, copyright, CRSwNP, cut, debilitating, decided, Dermira, determinable, discounted, disregarded, drawn, ECLIPSE, element, emergency, eosinophilic, exacerbation, exceeded, exercising, FASB, FASENRA, FceRI, fevipiprant, floating, formed, formula, franchise, free, frequent, GDP, goodwill, Gossamer, gouging, headache, housing, IgE, impairment, inapplicable, indemnification, indemnified, indemnify, ineligible, infection, inhibiting, instrument, interaction, intervened, intraperiod, June, lebrikizumab, LEO, Likewise, linked, LLC, Loan, long, maintained, mepolizumab, minimal, NDA, negligence, neutropenia, Nevada, Nucala, Obama, obstructive, omalizumab, Oxford, palmoplantar, partially, passed, perpetual, persistent, Pfizer, Pharma, portion, postpone, prepayment, prospectively, pulmonary, Reauthorization, recognizing, refundable, Regeneron, reimburse, renew, renewal, repay, repealing, repeatedly, reslizumab, respiratory, retrospective, Roche, Schedule, serving, SGR, Silicon, simplify, statistically, step, strep, suffered, suggest, Sustainable, taxing, Teva, tezepelumab, throat, tract, tralokinumab, unfold, unlimited, upper, USD, Valley, vomiting, Wuhan, Xolair